Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | KDM1A | O60341 | 9/20 | 0.53 |
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22784451 | 1.00 | MEN1 (0.65) | MEN1KMT2AKDM1APRCPOPRM1 | |
| SCHEMBL30710370 | 0.88 | MEN1 (0.65) | MEN1KMT2AKDM1APRCPGID4 | |
| SCHEMBL22776238 | 0.85 | KDM1A (0.53) | MEN1KMT2AKDM1APRCPOPRM1 | |
| SCHEMBL29561026 | 0.85 | KDM1A (0.53) | MEN1KMT2AKDM1APRCPOPRM1 | |
| SCHEMBL22777145 | 0.85 | KDM1A (0.53) | MEN1KMT2AKDM1APRCPOPRM1 | |
| SCHEMBL22776035 | 0.85 | KDM1A (0.60) | MEN1KMT2AKDM1APRCPOPRM1 | |
| SCHEMBL30710254 | 0.82 | KMT2A (0.59) | MEN1KMT2AKDM1AOPRM1OPRD1 | |
| SCHEMBL3819993 | 0.79 | MEN1 (0.53) | MEN1KMT2AMAPKAPK2 | |
| SCHEMBL30710388 | 0.79 | MEN1 (0.55) | MEN1KMT2AKDM1AMAPKAPK2 | |
| SCHEMBL30710320 | 0.78 | MEN1 (0.53) | MEN1KMT2AKDM1APRCPOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | MEN1 1138/4885KMT2A 4519/4885KDM1A 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.